Human papillomavirus (HPV) early proteins (E6, E7, E1, E2, E5, L1, L2)

Human papillomavirus associated targets are a group of viral proteins encoded by the HPV genome, including primarily early (E6, E7, E1, E2, E5) and late (L1, L2) genes, which serve as the basis for therapeutic and prophylactic vaccine development. The oncoproteins E6 and E7 are the dominant targets for therapeutic strategies, as they are persistently expressed in HPV-infected and transformed cells and disrupt the normal cell cycle, contributing to oncogenesis through degradation of key cellular proteins such as p53 (via E6) and retinoblastoma protein (via E7). Therapeutic vaccines and novel immunotherapies are under development to induce cellular immune responses against these proteins to clear HPV infection or treat HPV-associated cancers, while prophylactic vaccines target L1 (major capsid protein) to induce protective neutralizing antibodies against the virus. Collectively, these targets play essential roles in viral replication, immune evasion, and cancer development, making them central to current and future therapeutic interventions for HPV-associated disease. Note: This entry describes a target set, not a singular molecular entity, and should ideally be partitioned into specific canonical protein targets (e.g., HPV type 16 E6 oncoprotein) for structured annotation. The current query's naming is imprecise and not aligned with single-canonical-target conventions.

Other names

HPV-associated targetsHPV oncoproteins (especially for E6 and E7)HPV antigens (E6, E7, E1, E2, E5, L1, L2)

Vaccine-induced cellular immunity, especially cytotoxic T lymphocyte response against HPV-infected cells expressing E6, E7, and other viral antigens; Prophylactic antibody-mediated neutralization of virus (L1 VLP-based vaccines)